Carolyn Kinkade

Ms. Carolyn Kinkade

Rutgers University
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2009 in Genes & Development
Verified
Journal Article
Closed access
PDF file
APAnna M. Puzio-Kuter
Anna M. Puzio-Kuter
MCMireia Castillo-Martin
Mireia Castillo-Martin
CKCarolyn Kinkade
Carolyn Kinkade
XWXi Wang
Xi Wang
TSTian Huai Shen
Tian Huai Shen
CACory Abate-Shen
Cory Abate-Shen
Although bladder cancer represents a serious health problem worldwide, relevant mouse models for investigating disease progression or therapeutic targets have been lacking. We show that combined deletion of p53 and Pten in bladder epithelium leads to invasive cancer in a novel mouse model. Inactivation of p53 and PTEN promotes tumorigenesis in human bladder cells and is correlated with poor survival in human tumors. Furthermore, the synergistic effects of p53 and Pten deletion are mediated by deregulation of mammalian target of rapamycin (mTOR) signaling, consistent with the ability of rapamycin to block bladder tumorigenesis in preclinical studies. Our integrated analyses of mouse and human bladder cancer provide a rationale for investigating mTOR inhibition for treatment of patients with invasive disease.

1 August 2008 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
CKCarolyn Kinkade
Carolyn Kinkade
MCMireia Castillo-Martin
Mireia Castillo-Martin
APAnna Puzio-Kuter
Anna Puzio-Kuter
JYJun Yan
Jun Yan
TFThomas H. Foster
Thomas H. Foster
CACory Abate-Shen
Cory Abate-Shen
The AKT/mammalian target of rapamycin (AKT/mTOR) and ERK MAPK signaling pathways have been shown to cooperate in prostate cancer progression and the transition to androgen-independent disease. We have now tested the effects of combinatorial inhibition of these pathways on prostate tumorigenicity by performing preclinical studies using a genetically engineered mouse model of prostate cancer. We report here that combination therapy using rapamycin, an inhibitor of mTOR, and PD0325901, an inhibitor of MAPK kinase 1 (MEK; the kinase directly upstream of ERK), inhibited cell growth in cultured prostate cancer cell lines and tumor growth particularly for androgen-independent prostate tumors in the mouse model. We further showed that such inhibition leads to inhibition of proliferation and upregulated expression of the apoptotic regulator Bcl-2–interacting mediator of cell death (Bim). Furthermore, analyses of human prostate cancer tissue microarrays demonstrated that AKT/mTOR and ERK MAPK signaling pathways are often coordinately deregulated during prostate cancer progression in humans. We therefore propose that combination therapy targeting AKT/mTOR and ERK MAPK signaling pathways may be an effective treatment for patients with advanced prostate cancer, in particular those with hormone-refractory disease.

5 August 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AAAlvaro Aytes
Alvaro Aytes
AMAntonina Mitrofanova
Antonina Mitrofanova
CKCarolyn Kinkade
Carolyn Kinkade
CLCeline Lefebvre
Celine Lefebvre
MLMing Lei
Ming Lei
CACory Abate-Shen
Cory Abate-Shen
Significance: Although locally invasive prostate cancer is nearly always curable, metastatic prostate cancer usually results in lethality. Our study investigates the temporal progression and molecular mechanisms underlying prostate cancer metastasis using a new genetically engineered mouse model. Using lineage-tracing analyses, we show that dissemination of tumor cells occurs early in cancer progression, and well before the occurrence of metastases. We further show that metastasis is temporally coincident with expression of the oncogenic ETS gene Etv4 , and that Etv4 promotes prostate cancer metastasis in vivo. Our findings suggest that Etv4 may be a target for therapeutic intervention in metastatic prostate cancer.

30 August 2012 in Cancer Research
Verified
Journal Article
Closed access
PDF file
NFNicolas Floc'H
Nicolas Floc'H
CKCarolyn Kinkade
Carolyn Kinkade
TKTakashi Kobayashi
Takashi Kobayashi
AAAlvaro Aytes
Alvaro Aytes
CLCeline Lefebvre
Celine Lefebvre
CACory Abate-Shen
Cory Abate-Shen
Although the prognosis for clinically localized prostate cancer is now favorable, there are still no curative treatments for castration-resistant prostate cancer (CRPC) and, therefore, it remains fatal. In this study, we investigate a new therapeutic approach for treatment of CRPC, which involves dual targeting of a major signaling pathway that is frequently deregulated in the disease. We found that dual targeting of the Akt and mTOR signaling pathways with their respective inhibitors, MK-2206 and ridaforolimus (MK-8669), is highly effective for inhibiting CRPC in preclinical studies in vivo using a refined genetically engineered mouse model of the disease. The efficacy of the combination treatment contrasts with their limited efficacy as single agents, since delivery of MK-2206 or MK-8669 individually had a modest impact in vivo on the overall tumor phenotype. In human prostate cancer cell lines, although not in the mouse model, the synergistic actions of MK-2206 and ridaforolimus (MK-8669) are due in part to limiting the mTORC2 feedback activation of Akt. Moreover, the effects of these drugs are mediated by inhibition of cellular proliferation via the retinoblastoma (Rb) pathway. Our findings suggest that dual targeting of the Akt and mTOR signaling pathways using MK-2206 and ridaforolimus (MK-8669) may be effective for treatment of CRPC, particularly for patients with deregulated Rb pathway activity. Cancer Res; 72(17); 4483–93. ©2012 AACR.

15 September 2012 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JWJingqiang Wang
Jingqiang Wang
TKTakashi Kobayashi
Takashi Kobayashi
NFNicolas Floc'H
Nicolas Floc'H
CKCarolyn Kinkade
Carolyn Kinkade
AAAlvaro Aytes
Alvaro Aytes
CACory Abate-Shen
Cory Abate-Shen
Both the PI3K → Akt → mTOR and mitogen-activated protein kinase (MAPK) signaling pathways are often deregulated in prostate tumors with poor prognosis. Here we describe a new genetically engineered mouse model of prostate cancer in which PI3K-Akt-mTOR signaling is activated by inducible disruption of PTEN, and extracellular signal-regulated kinase 1/2 (ERK1/2) MAPK signaling is activated by inducible expression of a BRAFV600E oncogene. These tissue-specific compound mutant mice develop lethal prostate tumors that are inherently resistant to castration. These tumors bypass cellular senescence and disseminate to lymph nodes, bone marrow, and lungs where they form overt metastases in approximately 30% of the cases. Activation of PI3K → Akt → mTOR and MAPK signaling pathways in these prostate tumors cooperate to upregulate c-Myc. Accordingly, therapeutic treatments with rapamycin and PD0325901 to target these pathways, respectively, attenuate c-Myc levels and reduce tumor and metastatic burden. Together, our findings suggest a generalized therapeutic approach to target c-Myc activation in prostate cancer by combinatorial targeting of the PI3K → Akt → mTOR and ERK1/2 MAPK signaling pathways. Cancer Res; 72(18); 4765–76. ©2012 AACR.

24 May 2021 in Toxins
Verified
Journal Article
Open access
PDF file
CKCarolyn Kinkade
Carolyn Kinkade
ZRZorimar Rivera-Núñez
Zorimar Rivera-Núñez
LGLudwik Gorcyzca
Ludwik Gorcyzca
LALauren Aleksunes
Lauren Aleksunes
EBEmily Barrett
Emily Barrett
Contamination of the world’s food supply and animal feed with mycotoxins is a growing concern as global temperatures rise and promote the growth of fungus. Zearalenone (ZEN), an estrogenic mycotoxin produced by Fusarium fungi, is a common contaminant of cereal grains and has also been detected at lower levels in meat, milk, and spices. ZEN’s synthetic derivative, zeranol, is used as a growth promoter in United States (US) and Canadian beef production. Experimental research suggests that ZEN and zeranol disrupt the endocrine and reproductive systems, leading to infertility, polycystic ovarian syndrome-like phenotypes, pregnancy loss, and low birth weight. With widespread human dietary exposure and growing experimental evidence of endocrine-disrupting properties, a comprehensive review of the impact of ZEN, zeranol, and their metabolites on the female reproductive system is warranted. The objective of this systematic review was to summarize the in vitro, in vivo, and epidemiological literature and evaluate the potential impact of ZEN, zeranol, and their metabolites (commonly referred to as mycoestrogens) on female reproductive outcomes. We conducted a systematic review (PROSPERO registration CRD42020166469) of the literature (2000–2020) following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The data sources were primary literature published in English obtained from searching PubMed, Web of Science, and Scopus. The ToxR tool was applied to assess risk of bias. In vitro and in vivo studies (n = 104) were identified and, overall, evidence consistently supported adverse effects of mycoestrogens on physiological processes, organs, and tissues associated with female reproduction. In non-pregnant animals, mycoestrogens alter follicular profiles in the ovary, disrupt estrus cycling, and increase myometrium thickness. Furthermore, during pregnancy, mycoestrogen exposure contributes to placental hemorrhage, stillbirth, and impaired fetal growth. No epidemiological studies fitting the inclusion criteria were identified.